- Home
- QRVO vs MDGL Comparison
QRVO vs MDGL Comparison
Compare QRVO & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QRVO
- MDGL
- Stock Information
- Founded
- QRVO 1957
- MDGL 2011
- Country
- QRVO United States
- MDGL United States
- Employees
- QRVO N/A
- MDGL N/A
- Industry
- QRVO Semiconductors
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- QRVO Technology
- MDGL Health Care
- Exchange
- QRVO Nasdaq
- MDGL Nasdaq
- Market Cap
- QRVO 7.1B
- MDGL 6.1B
- IPO Year
- QRVO 1997
- MDGL N/A
- Fundamental
- Price
- QRVO $85.28
- MDGL $298.40
- Analyst Decision
- QRVO Hold
- MDGL Strong Buy
- Analyst Count
- QRVO 20
- MDGL 9
- Target Price
- QRVO $89.84
- MDGL $420.63
- AVG Volume (30 Days)
- QRVO 1.6M
- MDGL 360.9K
- Earning Date
- QRVO 07-29-2025
- MDGL 08-05-2025
- Dividend Yield
- QRVO N/A
- MDGL N/A
- EPS Growth
- QRVO N/A
- MDGL N/A
- EPS
- QRVO 0.58
- MDGL N/A
- Revenue
- QRVO $3,718,971,000.00
- MDGL $317,383,000.00
- Revenue This Year
- QRVO $0.65
- MDGL $286.17
- Revenue Next Year
- QRVO $5.13
- MDGL $64.17
- P/E Ratio
- QRVO $147.74
- MDGL N/A
- Revenue Growth
- QRVO N/A
- MDGL N/A
- 52 Week Low
- QRVO $49.46
- MDGL $200.63
- 52 Week High
- QRVO $124.87
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- QRVO 48.69
- MDGL 45.49
- Support Level
- QRVO $86.19
- MDGL $307.43
- Resistance Level
- QRVO $88.94
- MDGL $357.91
- Average True Range (ATR)
- QRVO 2.08
- MDGL 14.09
- MACD
- QRVO -0.65
- MDGL -2.88
- Stochastic Oscillator
- QRVO 7.96
- MDGL 18.38
About QRVO Qorvo Inc.
Qorvo represents the combined entity of RF Micro Devices and TriQuint Semiconductor, which merged in January 2015. The company specializes in radio frequency filters, power amplifiers, and front-end modules used in many of the world's most advanced smartphones. Qorvo also has a suite of products sold into a variety of nonsmartphone end markets, such as wireless base stations, cable TV and networking equipment, and infrastructure and military applications.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.